Clinical trial / 2022
Three months of resveratrol supplementation did not reduce hormonal migraine burden, disability, or improve quality of life.
A randomized, double-blind, placebo-controlled crossover trial evaluated the effect of consuming 75 mg of resveratrol twice daily for three months versus placebo in 62 hormonal migraineurs. Outcomes included the hormonal migraine burden index (HMBI), Headache Impact Test-6™, Migraine Disability Assessment, and Migraine-Specific Quality of Life. No significant differences were observed between resveratrol and placebo for HMBI (p = 0.895) or any secondary disability and quality-of-life measures.
- Study type
- Randomized, double-blind, placebo-controlled crossover trial
- Who was studied
- 62 hormonal migraineurs (mean age: 37.5 ± 0.8 years)
- What was measured
- Hormonal migraine burden index, disability, and quality of life
THE PAPER
A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine.
Dzator JSA, Howe PRC, Coupland KG, Wong RHX. Nutrients, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.